FDA awards Novartis expanded approval for breast cancer therapy
Posted:
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers.
Voice AI company SuperDial helps billing and provider organizations reclaim time and revenue by replacing hours of insurer calls with end-to-end AI agents.
The debt and equity series A round was led by SignalFire, with participation from Slow Ventures, Box…
According to recent survey data pending review and publication (Rousmaniere et al. 2025) yet widely circulated, 48.7 percent of 499 U.S. respondents reported using LLMs (large language models) for psychological support in the preceding year. The majority did this for anxiety,…
Attendees
Sponsors and Exhibitors
Contact us